Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study

Area of Science:

• Oncology
• Hematology
• Anesthesiology

Background:

• Colorectal cancer patients often present with anemia pre-surgery, increasing transfusion requirements.
• Transfusion-induced immunosuppression may elevate morbidity and tumor relapse rates.
• Investigating epoetin alfa to correct anemia and minimize transfusions is crucial.

Purpose of the Study:

• To evaluate the efficacy of perioperative epoetin alfa in anemic colorectal cancer patients.
• To determine if epoetin alfa reduces allogeneic blood transfusion needs.
• To assess the impact on hemoglobin and hematocrit levels.

Main Methods:

• Randomized controlled trial involving 223 anemic colorectal cancer patients.
• Epoetin alfa (150 or 300 IU/kg/day) or placebo administered subcutaneously for 12 days.
• All patients received iron supplementation; hemoglobin, hematocrit, and transfusion units were recorded.

Main Results:

• The 300 IU/kg epoetin alfa group showed significantly higher hemoglobin and hematocrit levels pre- and post-surgery compared to controls.
• Patients receiving 300 IU/kg epoetin alfa required fewer perioperative (0.81 vs. 1.32 units) and postoperative transfusions (0.87 vs. 1.33 units).
• No significant transfusion reduction was observed in the 150 IU/kg group.

Conclusions:

• Preoperative epoetin alfa (300 IU/day) effectively increases hemoglobin and hematocrit in colorectal surgery patients.
• This regimen is associated with a reduced need for perioperative and postoperative transfusions.
• Epoetin alfa offers a potential strategy to mitigate transfusion-related risks in this patient population.